

# SHARING THE OHDSI JOURNEY AND A VISION OF EVIDENCE TODAY, NOT IN SEVERAL TOMORROWS

Hughes, N<sup>1</sup>, Prieto-Alhambra, D<sup>2</sup>, Diaz, C<sup>3</sup>, Rijnbeek, P<sup>4</sup>, on behalf of the EHDEN Consortium

1. Janssen R&D, Belgium 2. University of Oxford, UK 3. Synapse Research Management Partners, Madrid, Spain 4. Erasmus University Medical Centre, Rotterdam, The Netherlands

## 1 SOCIOTECHNICAL ARCHITECTURE

- EHDEN's federated network has grown to **140 Data Partners** in **26 countries** and **47 certified SMEs** in **19 countries**. Two final Data Partner calls will be held in 2022, targeting a final 200 or more Data Partners, and a final SME call has resulted in 20 additional SMEs to be certified in a consistent, reproducible and rigorous methodology of ETL to the CDM

- Currently, more than **500 million** anonymous health records are being harmonised to the OMOP Common Data Model
- Scheduled for launch at the OHDSI Europe 2022 Symposium, a **metadata-driven catalogue** of EHDEN Data Partners, with feasibility dashboards is the first module of the EHDEN Portal to support a research workflow across the network
- Incorporation of Data Quality Dashboard work in EHDEN/OHDSI to **enhance the ETL process** and granular understanding of its fidelity

## 2 EVIDENCE GENERATION

- EHDEN has contributed to more than **50 publications** since launch, as outputs of our evidence generation programme via use cases, study-a-thons, and evidence-a-thons in diverse therapeutic areas
- The programme has collaborated in **study-a-thons** in osteo, and rheumatoid arthritis, COVID-19 (with OHDSI), and prostate cancer (with IMI\_PIONEER and OHDSI), planning

- further in the remainder of the IMI programme
- Evidence-a-thon** ('e-thon's) programme to support Data Partners with newly mapped datasets to start their training via re-running studies and on standardised analytical pipeline is growing
- Use cases to develop methods on **Health Technology Assessment**, outcome standards, and prediction/federated learning are being developed further with publications expanding

## 3 VALUE PROPOSITION, SUSTAINABILITY & EDUCATION

- Ongoing work on stakeholder **value propositions** has supported operational and business planning for sustainability
- A **not-for-profit legal entity** established under Dutch law in late 2021 to transition to a post-IMI startup in 2024
- Our SME partners are working with their own customer bases

- on mapping to the OMOP CDM, as well as interacting with the wider OHDSI community and workgroups on tools, skills and methods developments
- The free **EHDEN Academy** is now being used in **>60 countries** worldwide with **>2,000 colleagues**, with a growing curriculum of learning pathways and courses around ETL, tools, skills & methods, as well as for the lay public, in HTA or Regulatory development. Educational metrics evaluation is being initiated


## BACKGROUND

Europe is an ocean of data, but a desert for analysis. In response to this, within the Innovative Medicines Initiative (IMI), the **public-private partnership**, EHDEN was created. Running from November 2018 to April 2024 prior to launching startup, it consists of **23 partners**, co-led by Erasmus Medical Centre, and Janssen.

EHDEN's mission is to create an **open science ecosystem via a federated network** of Data Partners with locally mapped datasets to the OMOP common data model (CDM), generating timely and reliable evidence at scale to impact on clinical practice for positive patient outcomes.

EHDEN is industrialising **adoption of the OMOP CDM**, and utilisation of the OHDSI standardised analytical pipeline, **operating across three pillars**, (1) Sociotechnical architecture development, (2) Evidence generation, and (3) Value proposition development, sustainability and training/education.

Figure 1: Geographical overview of EHDEN Data Partners mapping to the OMOP CDM



- The programme will conclude its Data Partner calls and aims to be working with **~200 Data Partners** and **~750 million** health records interoperable via the CDM with the global OHDSI network, with ~67 SMEs, all in ~30 countries
- A transitional phase to the not-for-profit legal entity as a **European Coordination Centre** supporting the operating model that facilitates an open science community and evidence generation at scale with rapid analysis through to research programmes
- Provision of **sustainable architecture** used by EHDEN and OHDSI across the research workflow under FAIR principles, and similar to that being developed or envisaged in Europe, such as the European Medicine's Agency's DARWIN EU network, and the European Health Data Space (EHDS)
- Ultimately a **self-actualised** and **self-sustaining European open science community** at scale, embedded within OHDSI Europe, national nodes and the global network

## CONCLUSION

EHDEN is impacting and delivering **now**, and not at the end of the IMI programme. A key indicator of success will be the plurality of support for clinical, regulatory, health technology assessment and outcomes decision-making. It is imperative for EHDEN to succeed in supporting the evolution of European healthcare, as well as collaborating with OHDSI in Europe and internationally for a global, open science community.

The project looks forward to *greening* the European analysis desert and transforming it into a flourishing garden for rapid decision-making.



Scan QR for more information about EHDEN can be found at: [www.ehden.eu](http://www.ehden.eu)

enquiries@ehden.eu    IMI\_EHDEN    @IMI\_EHDEN



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.